What are your top takeaways in GU Cancers from ASCO 2025?  

Here are the top 3 prostate cancer studies: AMPLITUDE. LBA5006: Attard and colleagues show that the PARP inhibitor niraparib plus abiraterone/prednisone delayed rPFS in men with mHSPC (HR 0.63, p = 0.0001), meaning this is the first ARPI/PARPI successful combination in this hormone-sensitive HRRm s...

Novel approaches to early-stage prostate cancer and NMIBC. CAN-2409 with valcyclovir with IMRT for int/high-risk prostate cancer - first addition in decades to improve DFS. Mito/BCG tx of NMIBC - interesting strategy with non-inferiority to standard BCG  and work with less BCG given shortag...

Top 3 GU presentations: ctDNA in NIAGARA study (Bladder cancer): Important biomarker data for ctDNA in MIBC. AMPLITUDE (Prostate Cancer): Important data establishing the benefit of a PARP inhibitor, HRR-altered mHSPC. 9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripa...

The three presentations that I liked the most are the following: LBA5006 - Phase 3 AMPLITUDE: I think this is a trial that has the potential to change the standard of care for that patient population with early introduction of niraparib in combination with abiraterone. 4505 - Final results of Ch...

AMPLITUDE trial: Niraparib + ADT/abiraterone for metastatic HSPC VIOLET trial: terbium-PSMA for metastatic CRPC Pasritamig (KLK2-directed T cell engager) for mCRPC

KEYNOTE-564: long-term follow-up. The study investigators presented the 5-year follow-up data for this trial. I think it is particularly important because now, with reasonable follow up we can fully understand if adjuvant IO therapy does indeed increase cure rates. There is a clear difference in p...